Skip to content
  • Clinical Studies
  • Schedule M
  • Stability Studies
  • Pharma GMP
  • Pharma Tips
  • Pharma Books
  • Pharma Validation
  • Pharma Regulatory

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • SOP Guidelines
    • SOP Development
    • SOP Training
    • SOP Compliance Monitoring
    • SOP Revision Processes
    • Pharmaceutical SOP templates
    • GMP documentation SOP
    • Data integrity SOP pharma
    • Manufacturing SOP pharmaceutical
    • FDA SOP guidance
    • eQMS SOP workflows
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • GMP Audit Findings
    • Non-Compliance
      • SOP Absence
      • Revision Control
      • Non-Adherence
      • Poor Writing
      • Training Failure
      • Data Integrity Gaps
      • Mismatch Between SOPs and Practice
      • Critical Operations
      • Regulatory Change
      • Emergency Changes
      • Third-Party SOPs
      • Inspection Readiness
      • Deviation Handling
      • CAPA Integration
      • Validation Alignment
      • System Integration
      • Uncontrolled Distribution
      • SOP Implementation Gaps
      • SOP Alignment with Validation
      • Change Control Linkage
  • Toggle search form

Analytical Method Development: Sink Condition Determination SOP – V 2.0

Posted on By

Analytical Method Development: Sink Condition Determination SOP – V 2.0

Standard Operating Procedure for Determining Sink Conditions in Dissolution Testing


Department Analytical Method Development
SOP No. SOP/AMD/102/2025
Supersedes SOP/AMD/102/2022
Page No. Page 1 of 14
Issue Date 19/05/2025
Effective Date 20/05/2025
Review Date 19/05/2026

1. Purpose

This SOP describes the procedure for determining sink conditions for dissolution method development. It ensures that dissolution media provides adequate capacity to solubilize the entire dose of the drug substance, thereby enabling accurate and

reproducible dissolution profiling.

2. Scope

This procedure applies to all oral solid dosage forms (tablets, capsules, granules) evaluated within the Analytical Method Development (AMD) department for new and generic drug development programs.

3. Responsibilities

  • Analytical Scientist: Executes solubility and sink studies, performs calculations, and recommends media suitability.
  • Reviewer: Verifies results and interpretations and confirms alignment with regulatory definitions.
  • QA Officer: Ensures the study is adequately documented for regulatory submission.
  • Head – AMD: Approves the use of selected dissolution media based on sink condition data.

See also  Analytical Method Development: SOP for Syringeability and Injectability Method Development - V 2.0

4. Accountability

The Head of Analytical Method Development is accountable for ensuring that all sink condition evaluations are conducted as per ICH, WHO, and FDA guidelines, and that appropriate decisions are made regarding dissolution media selection.

5. Procedure

5.1 Definition of Sink Condition

  1. Sink condition exists when the volume of the dissolution medium can dissolve at least three times the amount of drug substance in the dosage form.
  2. This ensures a constant concentration gradient and prevents saturation of the medium.
  3. The formula is: Sink Ratio = Solubility in Medium (mg/mL) / Required Concentration (mg/mL)
  4. If Sink Ratio ≥ 3, sink conditions are considered achieved.

5.2 Solubility Determination

  1. Prepare a series of media based on preliminary selection:
    • Purified water
    • 0.1N HCl
    • pH 4.5 acetate buffer
    • pH 6.8 phosphate buffer
    • 0.5% SLS in water (for poorly soluble APIs)
  2. Add excess API (approx. 5–10 times dose equivalent) into 100 mL of each medium.
  3. Shake at 100 rpm in a water bath shaker at 37 ± 0.5°C for 24 hours.
  4. Filter using 0.45 µm membrane filter, dilute appropriately, and analyze by validated UV or HPLC method.
  5. Record results in Annexure-1: Solubility Data Sheet.

5.3 Dose/Solubility Ratio Calculation

  1. Determine the drug strength (e.g., 100 mg per tablet) and solubility value (mg/mL).
  2. Calculate required volume to dissolve one dose: Dose (mg) ÷ Solubility (mg/mL).
  3. Determine if the standard dissolution volume (e.g., 900 mL) exceeds three times this value.
  4. Document calculation in Annexure-2: Sink Ratio Evaluation Form.
See also  Analytical Method Development: Handling Non-Pharmacopoeial Test Methods - V 2.0

5.4 Interpretation of Results

  1. If sink condition is achieved in a compendial medium, proceed with method development using that medium.
  2. If sink condition is not achieved:
    • Consider addition of surfactant
    • Change pH or buffer strength
    • Explore use of biorelevant media (FaSSIF/FeSSIF)
  3. Document all justification and supporting data in Annexure-3: Sink Condition Justification Log.

5.5 Documentation and Finalization

  1. Compile all solubility, calculation, and decision logs.
  2. Include in the method development report and submit to QA and Regulatory Affairs for filing support.
  3. Approved dissolution medium and sink condition rationale must be archived as per data retention policy.

6. Abbreviations

  • API: Active Pharmaceutical Ingredient
  • SLS: Sodium Lauryl Sulfate
  • FaSSIF: Fasted-State Simulated Intestinal Fluid
  • FeSSIF: Fed-State Simulated Intestinal Fluid
  • HPLC: High Performance Liquid Chromatography
  • SOP: Standard Operating Procedure

7. Documents

  1. Solubility Data Sheet – Annexure-1
  2. Sink Ratio Evaluation Form – Annexure-2
  3. Sink Condition Justification Log – Annexure-3
See also  Analytical Method Development: SOP for Preservative Efficacy in Eye Drops - V 2.0

8. References

  • ICH Q6A – Specifications: Test Procedures and Acceptance Criteria
  • USP <711> – Dissolution
  • FDA Dissolution Testing of Immediate Release Solid Oral Dosage Forms (1997)
  • WHO Technical Report Series 929, Annex 7

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: Solubility Data Sheet

Medium pH Solubility (mg/mL) Temperature (°C) Result
0.1N HCl 1.2 5.4 37 Pass
pH 6.8 buffer 6.8 1.1 37 Fail

Annexure-2: Sink Ratio Evaluation Form

Dose Strength (mg) Solubility (mg/mL) Required Volume (mL) Dissolution Volume (mL) Sink Ratio Status
100 5.4 18.52 900 48.6 Sink Achieved

Annexure-3: Sink Condition Justification Log

In pH 6.8 buffer, sink condition not achieved (Sink Ratio = 1.2). Media modified to include 0.5% SLS. New solubility = 6.2 mg/mL. Sink condition achieved (Sink Ratio = 55.3). Justification: surfactant addition supported by BCS Class II profile and FDA recommendations.

Revision History:

Revision Date Revision No. Details Reason Approved By
04/05/2025 2.0 Expanded annexures and added solubility testing detail Annual SOP Review
Analytical Method Development V 2.0 Tags:Analytical Method Development SOP, SOP for analytical calculations, SOP for analytical documentation, SOP for analytical instrument calibration, SOP for analytical instrument qualification, SOP for analytical method change control, SOP for analytical method deviation handling, SOP for analytical method documentation practices, SOP for analytical method lifecycle management, SOP for analytical method optimization, SOP for analytical method risk assessment, SOP for analytical method training and competency, SOP for analytical method transfer protocol, SOP for analytical method validation, SOP for forced degradation studies, SOP for HPLC method development, SOP for limit of detection (LOD) determination, SOP for limit of quantitation (LOQ) determination, SOP for method accuracy testing, SOP for method linearity assessment, SOP for method precision evaluation, SOP for method reproducibility, SOP for method robustness testing, SOP for method transfer, SOP for method verification, SOP for qualification of working standards, SOP for reference standard handling, SOP for specificity testing in analytical methods, SOP for stability indicating methods, SOP for system suitability testing

Post navigation

Previous Post: Creams: SOP for Preventing Contamination during Process Transfers – V 2.0
Next Post: BA-BE Studies: SOP for Short-Term Stability of Analyte – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • Analytical Method Development V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Elixers V 2.0
  • Gels V 2.0
  • Injectables V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version